A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Dolutegravir (Primary) ; Darunavir/ritonavir; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms D2EFT
- 14 Sep 2022 Planned End Date changed from 31 Jul 2024 to 31 Oct 2023.
- 14 Sep 2022 Planned primary completion date changed from 31 Jul 2023 to 31 Oct 2022.
- 20 Jun 2022 Planned End Date changed from 31 Dec 2024 to 31 Jul 2024.